/
AbCellera is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. We have built a platform for advancing antibody drug programs that we believe provides us with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel moda…
The business is unprofitable at the operating level (-288.98% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 160.6% YoY with margins expanding 802.7pp.
Negative free cash flow of -$174M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$79M
▲ +160.6% YoY
Net Income (TTM)
-$144M
▲ +10.1% YoY
Op. Margin
-267.60%
▲ +802.7pp YoY
ROIC
-15.07%
▲ +5.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$189M
▲ +6.9% YoY
Op. Cash Flow (TTM)
-$153M
▼ -20.9% YoY
Net Debt
$63M
Cash & Equiv.
$77M
5Y CAGR: -20.3%
Continue Research